Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

U.S. Renal Care is a leading provider of in-center and home dialysis in the United States

CAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation's fastest-growing dialysis provider, today announced entry into a multi-year commercial supply contract encompassing all USRC dialysis centers. The contract enables USRC attending physicians to prescribe Vafseo® for patients on dialysis as deemed clinically appropriate when it is expected to be available in January 2025.

In March 2024, Vafseo was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Akebia expects to receive Transitional Drug Add-on Payment Adjustment designation for Vafseo in January 2025.

"We are excited to deliver a new choice in anemia management for dialysis patients and are extremely pleased to have entered into this supply agreement with U.S. Renal Care," said John P. Butler, Chief Executive Officer of Akebia. "We see USRC at the forefront of innovative care for patients on dialysis and we are pleased that they recognize Vafseo as an important option to make available for their patients. We believe that commitment to innovation will allow nearly 2000 nephrologists access to prescribe Vafseo for patients living with kidney disease, as clinically appropriate."

"U.S. Renal Care is pleased to partner with Akebia to make Vafseo accessible to our patients," said Mark Caputo, Chief Executive Officer, U.S. Renal Care. "Our Office of the Chief Medical Officer and teams of medical professionals are actively working on a protocol for Vafseo, and we believe nephrologists are eager to gain experience with an oral treatment that has the potential to advance the treatment of anemia due to CKD in dialysis patients."

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About U.S. Renal Care
U.S. Renal Care, the fastest-growing dialysis provider in the nation, partners with nephrologists to care for more than 36,000 people living with kidney disease across 32 states in the U.S. Since 2000, U.S. Renal Care has been a leader in clinical quality, innovation, and operational excellence – delivering the best experience and outcomes for its patients.  Visit USRenalCare.com to learn more. 

About Vafseo® (vadadustat) Tablets 
Vafseo^® (vadadustat) Tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that ...

Full story available on Benzinga.com